相似文献
1
Oral cyclosporine A--the current picture of its liposomal and other delivery systems.
Cell Mol Biol Lett. 2009;14(1):139-52. doi: 10.2478/s11658-008-0041-6. Epub 2008 Nov 12.
2
Advanced delivery of ciclosporin A: present state and perspective.
Expert Opin Drug Deliv. 2007 Jul;4(4):349-58. doi: 10.1517/17425247.4.4.349.
3
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
Drug Discov Today. 2006 Sep;11(17-18):846-54. doi: 10.1016/j.drudis.2006.07.015.
4
Double loading of cyclosporine A in liposomes using cyclodextrin complexes.
PDA J Pharm Sci Technol. 2009 Mar-Apr;63(2):139-48.
5
Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange.
Transplantation. 1995 Nov 15;60(9):999-1006.
6
Cyclosporine A delivery to the eye: a pharmaceutical challenge.
Eur J Pharm Biopharm. 2003 Nov;56(3):307-18. doi: 10.1016/s0939-6411(03)00138-3.
7
Drug delivery systems for cyclosporine: achievements and complications.
J Drug Target. 1998;5(6):443-58. doi: 10.3109/10611869808997871.
8
Recent advances in cyclosporine drug delivery: challenges and opportunities.
Drug Deliv Transl Res. 2019 Dec;9(6):1067-1081. doi: 10.1007/s13346-019-00650-1.
9
Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
Arch Pharm Res. 2010 Nov;33(11):1835-42. doi: 10.1007/s12272-010-1116-2. Epub 2010 Nov 30.
10
Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.
Eur J Pharm Sci. 2005 Nov;26(3-4):251-65. doi: 10.1016/j.ejps.2005.05.012.
引用本文的文献
1
Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.
Drugs R D. 2025 Mar;25(1):1-17. doi: 10.1007/s40268-024-00495-1. Epub 2024 Dec 24.
2
Studies on cationic ocular emulsions containing bipartitioned oil droplets to codeliver cyclosporin A and etodolac.
Nanomedicine (Lond). 2024;19(12):1035-1050. doi: 10.2217/nnm-2023-0364. Epub 2024 Apr 30.
3
Membrane-Fusing Vehicles for Re-Sensitizing Transporter-Mediated Multiple-Drug Resistance in Cancer.
Pharmaceutics. 2024 Apr 2;16(4):493. doi: 10.3390/pharmaceutics16040493.
4
Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A.
AAPS PharmSciTech. 2024 Feb 1;25(2):28. doi: 10.1208/s12249-024-02738-5.
5
The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs.
Int J Mol Sci. 2024 Jan 9;25(2):815. doi: 10.3390/ijms25020815.
6
Review of two immunosuppressants: tacrolimus and cyclosporine.
J Korean Assoc Oral Maxillofac Surg. 2023 Dec 31;49(6):311-323. doi: 10.5125/jkaoms.2023.49.6.311.
7
Drug transport by red blood cells.
Front Physiol. 2023 Dec 11;14:1308632. doi: 10.3389/fphys.2023.1308632. eCollection 2023.
8
Exploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review.
Saudi Pharm J. 2023 Dec;31(12):101870. doi: 10.1016/j.jsps.2023.101870. Epub 2023 Nov 10.
9
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro.
Pharmaceutics. 2023 Mar 22;15(3):1023. doi: 10.3390/pharmaceutics15031023.
10
Cyclosporine A Delivery Platform for Veterinary Ophthalmology-A New Concept for Advanced Ophthalmology.
Biomolecules. 2022 Oct 20;12(10):1525. doi: 10.3390/biom12101525.
本文引用的文献
1
Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporin A at 0.96-A resolution.
Proteins. 2008 Mar;70(4):1635-9. doi: 10.1002/prot.21855.
2
Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability.
Int J Pharm. 2007 Dec 10;345(1-2):134-41. doi: 10.1016/j.ijpharm.2007.08.050. Epub 2007 Sep 4.
3
Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
Eur J Pharm Biopharm. 2008 Mar;68(3):535-44. doi: 10.1016/j.ejpb.2007.07.006. Epub 2007 Jul 17.
4
PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
J Control Release. 2007 Jun 4;119(2):197-206. doi: 10.1016/j.jconrel.2007.02.004. Epub 2007 Feb 14.
5
Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A.
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2967-73. doi: 10.1166/jnn.2006.403.
6
Enhancement of dissolution of cyclosporine A using solid dispersions with polyoxyethylene (40) stearate.
Pharmazie. 2006 Aug;61(8):681-4.
7
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
Drug Discov Today. 2006 Sep;11(17-18):846-54. doi: 10.1016/j.drudis.2006.07.015.
8
Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid.
Int J Pharm. 2006 Sep 28;322(1-2):146-53. doi: 10.1016/j.ijpharm.2006.05.021. Epub 2006 May 16.
9
Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds.
Biomacromolecules. 2006 May;7(5):1509-20. doi: 10.1021/bm060130l.
10
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
Int J Pharm. 2006 Jul 6;317(1):82-9. doi: 10.1016/j.ijpharm.2006.02.045. Epub 2006 Mar 31.
Zotero 插件